TSE:ATB - Atrium Innovations Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Atrium Innovations logoAtrium Innovations Inc. (Atrium) is a Canada-based company engaged in the development, manufacturing, and commercialization of dietary supplements endorsed by health professionals. The Company owns more than 16 brands of products which are distributed mainly in the healthcare practitioner and health food and specialized store channels in more than 35 countries, with a primary focus in North America and Europe. The Company manufactures and markets more than 2,000 health and nutrition finished products. The products are generated primarily from natural sources and include vitamins, minerals and specialized products such as enzymes, probiotics and omega-3. In October 2013, the Company announced that it has acquired 70% interest of Mucos Pharma CZ s.r.o. In February 2014, Atrium Innovations Inc announced the completion of the acquisition of Atrium by corporations backed by the Permirafunds.

Receive ATB News and Ratings via Email

Sign-up to receive the latest news and ratings for ATB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange TSE
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolTSE:ATB
CUSIPN/A
Phone+1-514-2056240

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market CapC$0.00

Atrium Innovations (TSE:ATB) Frequently Asked Questions

What is Atrium Innovations' stock symbol?

Atrium Innovations trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ATB."

Has Atrium Innovations been receiving favorable news coverage?

News stories about ATB stock have trended somewhat positive on Sunday, Accern Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Atrium Innovations earned a media and rumor sentiment score of 0.12 on Accern's scale. They also gave news stories about the company an impact score of 45.89 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for Atrium Innovations.

How do I buy shares of Atrium Innovations?

Shares of ATB and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

How can I contact Atrium Innovations?

Atrium Innovations' mailing address is 3500 de Maisonneuve Blvd W Suite 2405, WESTMOUNT, QC H3Z 3C1, Canada. The company can be reached via phone at +1-514-2056240.


MarketBeat Community Rating for Atrium Innovations (TSE ATB)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  70 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  151
MarketBeat's community ratings are surveys of what our community members think about Atrium Innovations and other stocks. Vote "Outperform" if you believe ATB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.